LDLR and metabolic dysfunction-associated steatohepatitis: We recently reported that the capacity of dietary docosahexaenoic acid (DHA; 22:6,n-3) to suppress markers of hepatic damage (plasma alanine [ALT] and aspartate [AST] amino-transferases), hepatic inflammation (C-type lectin domain family 4-F [Clec4F], F4/80, toll-like receptor 4 [TLR4]), oxidative stress (NADPH oxidase subunits NOX2, p22phox, p40phox, p47phox, and p67phox), and fibrosis (pro-collagen 1A1 [proCol1A1], transforming growth-factor β1 [TGF β1]) was greater than dietary eicosapentaenoic acid (EPA, 20:5,n-3) using the LDLR-/- mouse model of western diet (WD) induced NASH [8].